Basic HTML Version
HYPNOTIC ANALGESIA IN PERSONS WITH DISABILITIES
217
Table 2
Means and SDs for the Secondary Outcome Measures at Prebaseline, Postbaseline, Posttreatment, and 3-Month Follow-Up, Intent-to-Treat and
Efficacy Analyses
Measure
Prebaseline
Mean (SD)
Postbaseline/
Pretreatment
Mean (SD)
Posttreatment
Mean (SD)
3-Month
Follow-up
Mean (SD)
F (df)
Intent-to-Treat Analysis (
n
= 30)
Pain unpleasantness (NRS-11)
4.46
a
(2.05)
4.80
a
(2.11)
3.71
b
(2.26)
3.61
b
(2.55)
4.52* (3, 27)
Pain interference (BPI)
38.87
a
(19.45)
32.61
ac
(23.23)
28.17
bc
(20.70)
27.83
bc
(21.08)
4.15* (3, 27)
Depression (CES-D)
18.77 (10.63)
17.34 (10.49)
15.60 (9.35)
16.70 (11.87)
0.95 (3, 27)
Perceived Control Over Pain
2.16 (0.61)
2.19 (0.62)
2.51 (0.70)
2.40 (0.87)
2.59 (3, 27)
(SOPA Control)
Efficacy Analysis (
n
= 27)
Pain unpleasantness (NRS-11)
4.33
a
(2.09)
5.56
a
(2.01)
3.41
b
(2.23)
3.43
b
(2.50)
3.92* (3, 23)
Pain interference (BPI)
37.69
a
(18.29)
29.54
b
(21.12)
25.92
b
(18.84)
25.04
b
(18.22)
5.07** (3, 23)
Depression (CES-D)
17.77 (9.50)
16.55(9.79)
14.73 (8.70)
14.92 (9.85)
0.71 (3, 23)
Perceived control over pain
2.13
a
(0.62)
2.18
a
(0.63)
2.57
b
(0.71)
2.44
b
(0.90)
3.74* (3, 23)
(SOPA Control)
Note.
BPI = Brief Pain Inventory Pain Interference scale; CES-D = Center for Epidemiologic Studies Depression scale; SOPA Control = Control scale of the
Survey of Pain Attitudes; NRS-11 = 1–10 Numerical Rating Scale of pain unpleasantness. Means with different subscripts are significantly different (p < .05)
from one another.
**
p
< .01.